

Dear Ms. Eide,

It has come to my attention that there is a vote on the 15<sup>th</sup> regarding Medicaid coverage for Ingrezza. As a Neurologist in northern Idaho who sees a large Medicaid population I feel we need continued coverage for our patients.

There is strong data that this medication is efficacious in patients with tardive dyskinesia and I have seen a robust response to this medication.

A further concern of mine is the growing use of neuroleptic medications especially in our younger population with patients now presenting with TD earlier in life.

We must have this medication as an option to treat these unfortunate patients.

Thank you,

Jean Thomas, M.D.

St. Joseph Regional Medical Center

Lewiston